Advanced Therapies Manufacturing Capacity in North America by Phacilitate

Advanced Therapies Manufacturing Capacity in North America

A comprehensive guide showcasing the growing cell and gene therapy and viral vector manufacturing landscape in North America

  
Phacilitate CDMO map of North America advanced therapies manufacturing


Welcome to the 2020 edition of Phacilitate’s ‘Manufacturing Advanced Therapies in North America’ map; a visual guide of service providers covering your needs for advanced cell and gene therapy manufacturing. Whether you need a vector made or need a place for your clinical trial patient product to be produced, let us guide you through some of the region’s leading providers. This map contains a range of qualified companies that have been servicing the cell and gene therapy space for decades.

 
 
We all have faced that moment when your clinical design is coming into focus and suddenly you realise that getting your vector made on time or finding enough capacity to manufacture your therapy is proving to be more challenging then you expected. Listed on this map are fully GMP compliant, experienced organisations with a host of information about capacity, quality systems, specialist services and, of course, contact details for you to start that all-important conversation. Here’s an overview of some of the 18 companies featured:
 
If your needs are for vector manufacturing check out:
  • Aldevron
  • VGXI
  • Waisman Biomanufacturing
  • Vigene Biosciences
  • Cognate Bioservices
  • Catalent Cell & Gene Therapy

If you are looking into non-viral gene-modified therapies or need GMP proteins take a look at:
  • Bio-Techne
 

For services related to clinical trial patient processing:
  • CCRM
  • Minaris Regenerative Medicine
  • Bio-Techne
  • Cognate Bioservices
  • Lonza
  • KBI Biopharma
  • WuXi Advanced Therapies
   

For other cell and gene therapy GMP manufacturing providers see what is available at: 
  • MilliporeSigma
  • C3i
  • Waisman Biomanufacturing
  • FUJIFILM Diosynth Biotechnologies
 
These companies have been able to maintain their operations during these difficult times of Covid-19. They have put into place additional safety mechanisms to ensure the utmost safety in processing your cells and/or manufacturing your vectors.
 

Kindest regards and stay safe,
 
Jeff Liter, Sr. Advisor
Bio-Techne

Jeff Litter, bio-techne foreword for Phacilitate's manufacturing capacities in North America map


Have you seen the Europe edition?
 
PHACILITATE CDMO Europe map advanced therapies manufacturing